Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypoxanthine phosphoribosyltransferase 1 pseudogene 3 (HPRT1P3) is classified as a pseudogene, meaning it is a non-functional copy or copy fragment of a functional gene, in this case related to hypoxanthine phosphoribosyltransferase 1 (HPRT1)[1]. Pseudogenes typically exhibit sequence similarity to their parent gene but contain mutations, frameshifts, or other defects that render them incapable of protein-coding or biological function[3]. HPRT1P3 is not believed to have a direct biological role, nor is it considered a therapeutic target or clinically relevant biomarker[1][3]. There is currently no evidence it is involved in any disease or that it interacts with drugs. As a pseudogene, it serves primarily as a genomic remnant and is sometimes used as a reference in studies of gene evolution, gene duplication, or pseudogene classification[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxanthine phosphoribosyltransferase 1 pseudogene 3 (HPRT1P3).